Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shujing Liu

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
Journal for Immunotherapy of Cancer|December 23, 2021
Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC functionHuaishan Wang, Hui Chen, Shujing Liu, et al.
Science Advances|January 15, 2025
Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cellsYeye Guo, Huaishan Wang, Shujing Liu, et al.
Cell Reports|October 8, 2023
Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunityWenqun Zhong, Youtao Lu, Xuexiang Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2017
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid TumorsClinton Yam, Xiaowei Xu, Michael A Davies, et al.
Nature Communications|July 14, 2022
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8<sup>+</sup> T-cell infiltration into tumorsLei Guan, Bin Wu, Ting Li, et al.
Cancer Discovery|December 20, 2018
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant MelanomaRani Ojha, Nektaria M Leli, Angelique Onorati, et al.
Nature Communications|March 13, 2019
Author Correction: Loss of Phd2 cooperates with BRAF<sup>V600E</sup> to drive melanomagenesisShujing Liu, Gao Zhang, Jianping Guo, et al.
Nature Communications|December 22, 2018
Loss of Phd2 cooperates with BRAF<sup>V600E</sup> to drive melanomagenesisShujing Liu, Gao Zhang, Jianping Guo, et al.
Cell Host & Microbe|October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patientsAngeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
Cancer Discovery|September 14, 2017
A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling RolesVito W Rebecca, Michael C Nicastri, Noel McLaughlin, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Journal for Immunotherapy of Cancer|December 23, 2021
Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC functionHuaishan Wang, Hui Chen, Shujing Liu, et al.
Science Advances|January 15, 2025
Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cellsYeye Guo, Huaishan Wang, Shujing Liu, et al.
Cell Reports|October 8, 2023
Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunityWenqun Zhong, Youtao Lu, Xuexiang Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2017
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid TumorsClinton Yam, Xiaowei Xu, Michael A Davies, et al.
Nature Communications|July 14, 2022
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8<sup>+</sup> T-cell infiltration into tumorsLei Guan, Bin Wu, Ting Li, et al.
Cancer Discovery|December 20, 2018
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant MelanomaRani Ojha, Nektaria M Leli, Angelique Onorati, et al.
Nature Communications|March 13, 2019
Author Correction: Loss of Phd2 cooperates with BRAF<sup>V600E</sup> to drive melanomagenesisShujing Liu, Gao Zhang, Jianping Guo, et al.
Nature Communications|December 22, 2018
Loss of Phd2 cooperates with BRAF<sup>V600E</sup> to drive melanomagenesisShujing Liu, Gao Zhang, Jianping Guo, et al.
Cell Host & Microbe|October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patientsAngeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
Cancer Discovery|September 14, 2017
A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling RolesVito W Rebecca, Michael C Nicastri, Noel McLaughlin, et al.
Pageof 17